Wenzhou Municipal Key Laboratory of Pediatric Pharmacy, Department of Pharmacy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325027, China; The Second School of Medicine, Wenzhou Medical University, Wenzhou, China.
Wenzhou Municipal Key Laboratory of Pediatric Pharmacy, Department of Pharmacy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325027, China; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
Colloids Surf B Biointerfaces. 2024 May;237:113869. doi: 10.1016/j.colsurfb.2024.113869. Epub 2024 Mar 21.
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are serious lung injuries caused by various factors, leading to increased permeability of the alveolar-capillary barrier, reduced stability of the alveoli, inflammatory response, and hypoxemia. Despite several decades of research since ARDS was first formally described in 1967, reliable clinical treatment options are still lacking. Currently, supportive therapy and mechanical ventilation are prioritized, and there is no medication that can be completely effective in clinical treatment. In recent years, nanomedicine has developed rapidly and has exciting preclinical treatment capabilities. Using a drug delivery system based on nanobiotechnology, local drugs can be continuously released in lung tissue at therapeutic levels, reducing the frequency of administration and improving patient compliance. Furthermore, this novel drug delivery system can target specific sites and reduce systemic side effects. Currently, many nanomedicine treatment options for ARDS have demonstrated efficacy. This review briefly introduces the pathophysiology of ARDS, discusses various research progress on using nanomedicine to treat ARDS, and anticipates future developments in related fields.
急性肺损伤（ALI）和急性呼吸窘迫综合征（ARDS）是由多种因素引起的严重肺部损伤，导致肺泡-毛细血管屏障通透性增加、肺泡稳定性降低、炎症反应和低氧血症。尽管自 1967 年首次正式描述 ARDS 以来已经进行了几十年的研究，但仍然缺乏可靠的临床治疗选择。目前，以支持性治疗和机械通气为优先事项，并且没有一种药物在临床治疗中能够完全有效。近年来，纳米医学发展迅速，具有令人兴奋的临床前治疗能力。使用基于纳米生物技术的药物输送系统，可以在肺组织中以治疗水平持续释放局部药物，减少给药频率并提高患者的依从性。此外，这种新型药物输送系统可以靶向特定部位并减少全身副作用。目前，许多用于 ARDS 的纳米医学治疗方法已经显示出疗效。本文简要介绍了 ARDS 的病理生理学，讨论了使用纳米医学治疗 ARDS 的各种研究进展，并对相关领域的未来发展进行了展望。
